Long non-coding RNA nuclear enriched abundant transcript 1 (NEAT1) sponges microRNA-124-3p to up-regulate phosphodiesterase 4B (PDE4B) to accelerate the progression of Parkinson’s disease

Chen, Mingyu; Fan, Kai; Zhao, Lian-Jiang; Wei, Jie-Mei; Ji-xu, Gao; Li, Zhen-Fu

doi:10.1080/21655979.2021.1883279

Cited by 34 publications

(19 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most algorithms embedded in tools are based on splitting the reads (reads spanning BSJs are split into segments and are aligned to the reference sequence in reverse order) (called segmented-read-based), while several other tools are based on a pre-defined BSJ and flanking sequence of a circRNA (pseudo-sequences to recognize BSJ reads). These tools then map the read directly to that pseudo-reference for discovering a BSJ [28,31,57].…”

Section: Characteristics Of Lncrna and Circrnamentioning

confidence: 99%

“…Another essential mechanism of indirect modulation is via the "sponge effect of lncRNA", that is, one lncRNA can bind a large set of miRNAs and alter their activities. For example, Chen et al [31] found that the lncRNA nuclear enriched abundant transcript 1 (NEAT1) could upregulate phosphodiesterase 4B (PDE4B) expression to accelerate the progression of PD by sponging miRNA-124-3p [31] and miR-374c-5p [45]. A well-known lncRNA, RNA X-inactive-specific transcript (XIST), exhibits antiinflammatory properties by regulating the aforementioned miR-29c-3p, altering NFAT protein levels and overactivating the NLRP3 inflammasome in a rat model of epilepsy and a neuronal cell culture [229].…”

Section: Mirna-lncrna Interactionsmentioning

confidence: 99%

See 1 more Smart Citation

The role of noncoding RNAs in Parkinson’s disease: biomarkers and associations with pathogenic pathways

et al. 2021

View full text Add to dashboard Cite

The discovery of various noncoding RNAs (ncRNAs) and their biological implications is a growing area in cell biology. Increasing evidence has revealed canonical and noncanonical functions of long and small ncRNAs, including microRNAs, long ncRNAs (lncRNAs), circular RNAs, PIWI-interacting RNAs, and tRNA-derived fragments. These ncRNAs have the ability to regulate gene expression and modify metabolic pathways. Thus, they may have important roles as diagnostic biomarkers or therapeutic targets in various diseases, including neurodegenerative disorders, especially Parkinson’s disease. Recently, through diverse sequencing technologies and a wide variety of bioinformatic analytical tools, such as reverse transcriptase quantitative PCR, microarrays, next-generation sequencing and long-read sequencing, numerous ncRNAs have been shown to be associated with neurodegenerative disorders, including Parkinson’s disease. In this review article, we will first introduce the biogenesis of different ncRNAs, including microRNAs, PIWI-interacting RNAs, circular RNAs, long noncoding RNAs, and tRNA-derived fragments. The pros and cons of the detection platforms of ncRNAs and the reproducibility of bioinformatic analytical tools will be discussed in the second part. Finally, the recent discovery of numerous PD-associated ncRNAs and their association with the diagnosis and pathophysiology of PD are reviewed, and microRNAs and long ncRNAs that are transported by exosomes in biofluids are particularly emphasized.

show abstract

Section: Characteristics Of Lncrna and Circrnamentioning

confidence: 99%

Section: Mirna-lncrna Interactionsmentioning

confidence: 99%

The role of noncoding RNAs in Parkinson’s disease: biomarkers and associations with pathogenic pathways

et al. 2021

View full text Add to dashboard Cite

show abstract

“…On the other hand, recent studies have discovered the involvement of several lncRNA species in Parkinson’s pathology. For instance, NEAT1 levels were significantly upregulated in the peripheral blood of PD patients [ 98 ] and has been shown to sponge miR-124 to accelerate Parkinson’s pathology [ 99 ]. Homeobox (HOX) transcript antisense RNA (HOTAIR), ~2.2kb nucleotide long non-coding transcript found at the HOXC genetic locus has been reported in PD progression [ 100 ].…”

Section: Ncrnas Implicated In Neurological Disordersmentioning

confidence: 99%

Non-coding RNAs and their bioengineering applications for neurological diseases

Das

Khodarkovskaya

et al. 2021

Bioengineered

View full text Add to dashboard Cite

Engineering of cellular biomolecules is an emerging landscape presenting creative therapeutic opportunities. Recently, several strategies such as biomimetic materials, drug-releasing scaffolds, stem cells, and dynamic culture systems have been developed to improve specific biological functions, however, have been confounded with fundamental and technical roadblocks. Rapidly emerging investigations on the bioengineering prospects of mammalian ribonucleic acid (RNA) is expected to result in significant biomedical advances. More specifically, the current trend focuses on devising non-coding (nc) RNAs as therapeutic candidates for complex neurological diseases. Given the pleiotropic and regulatory role, ncRNAs such as microRNAs and long non-coding RNAs are deemed as attractive therapeutic candidates. Currently, the list of non-coding RNAs in mammals is evolving, which presents the plethora of hidden possibilities including their scope in biomedicine. Herein, we critically review on the emerging repertoire of ncRNAs in neurological diseases such as Alzheimer’s disease, Parkinson’s disease, neuroinflammation and drug abuse disorders. Importantly, we present the advances in engineering of ncRNAs to improve their biocompatibility and therapeutic feasibility as well as provide key insights into the applications of bioengineered non-coding RNAs that are investigated for neurological diseases.

show abstract

“…NEAT1 is another lncRNA that is overexpressed in PD patients. Several studies demonstrated that its downregulation represses α-syn-induced activation of NLRP3 inflammation, apoptosis, and cytotoxicity by targeting miR-1301-3p, the miR-212-5p/RAB3IP axis, miR-124-3p and miR-212-3p [ 179 , 180 , 181 ]. The deregulation of NEAT1 downregulates microRNA-212-3p to accelerate the progression of PD.…”

Section: Epigenetic Alterations In Parkinson’s Diseasementioning

confidence: 99%

“…The deregulation of NEAT1 downregulates microRNA-212-3p to accelerate the progression of PD. The knockdown of NEAT1 negatively affects the expression of AXIN1 , a target of miR-212_3p reversing the suppression effect [ 179 ], meaning that the deregulation of this lncRNA is associated with PD development, characterizing it as a candidate therapeutic target. Furthermore, increased levels of NEAT1 were also detected in peripheral blood cells of patients with PD [ 182 ], revealing its potential as a PD progression biomarker.…”

Section: Epigenetic Alterations In Parkinson’s Diseasementioning

confidence: 99%

Nuclear and Mitochondrial Genome, Epigenome and Gut Microbiome: Emerging Molecular Biomarkers for Parkinson’s Disease

Cabral

Schaan

Cavalcante

et al. 2021

IJMS

View full text Add to dashboard Cite

Background: Parkinson’s disease (PD) is currently the second most common neurodegenerative disorder, burdening about 10 million elderly individuals worldwide. The multifactorial nature of PD poses a difficult obstacle for understanding the mechanisms involved in its onset and progression. Currently, diagnosis depends on the appearance of clinical signs, some of which are shared among various neurologic disorders, hindering early diagnosis. There are no effective tools to prevent PD onset, detect the disease in early stages or accurately report the risk of disease progression. Hence, there is an increasing demand for biomarkers that may identify disease onset and progression, as treatment-based medicine may not be the best approach for PD. Over the last few decades, the search for molecular markers to predict susceptibility, aid in accurate diagnosis and evaluate the progress of PD have intensified, but strategies aimed to improve individualized patient care have not yet been established. Conclusions: Genomic variation, regulation by epigenomic mechanisms, as well as the influence of the host gut microbiome seem to have a crucial role in the onset and progress of PD, thus are considered potential biomarkers. As such, the human nuclear and mitochondrial genome, epigenome, and the host gut microbiome might be the key elements to the rise of personalized medicine for PD patients.

show abstract

Long non-coding RNA nuclear enriched abundant transcript 1 (NEAT1) sponges microRNA-124-3p to up-regulate phosphodiesterase 4B (PDE4B) to accelerate the progression of Parkinson’s disease

Abstract: 2021) Long non-coding RNA nuclear enriched abundant transcript 1 (NEAT1) sponges microRNA-124-3p to up-regulate phosphodiesterase 4B (PDE4B) to accelerate the progression of

Cited by 34 publications

References 44 publications

The role of noncoding RNAs in Parkinson’s disease: biomarkers and associations with pathogenic pathways

The role of noncoding RNAs in Parkinson’s disease: biomarkers and associations with pathogenic pathways

Non-coding RNAs and their bioengineering applications for neurological diseases

Nuclear and Mitochondrial Genome, Epigenome and Gut Microbiome: Emerging Molecular Biomarkers for Parkinson’s Disease

Contact Info

Product

Resources

About